It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

With the Canadian economy experiencing a contraction in November and a recent interest rate cut by the Bank of Canada due to tariff uncertainties, investors are navigating a complex landscape. In such ...

This is common. Those of us in research routinely store patient samples — blood, fluids, tissue, scrapings, and other ...

New licensing Guidelines issued by the National Institutes of Health at the end of the Biden Administration could harm ...

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.

groninger, a German manufacturer of filling and closing machines for the pharmaceutical, consumer healthcare and cosmetics industries, is expanding its U.S. headquarters in Charlotte. groninger USA ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Kevin Koch, the President and CEO of Edgewise Therapeutics , Inc. (NASDAQ:EWTX), a biotechnology company with a market capitalization of $2.5 billion, recently executed a series of stock transactions, ...

Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.